Clincosm LogoSign in Get a demo

PEACH: Postbariatric EArly Discharge Controlled by Healthdot

Sponsor
Philips Electronics Nederland B.V. acting through Philips CTO organization (Industry)
Overall Status
Completed
CT.gov ID
NCT04754893
Collaborator
(none)
208
Enrollment
1
Location
2
Arms
10.1
Actual Duration (Months)
20.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This clinical investigation is a single center patient preference trial in a tertiary hospital in the Netherlands, designed to compare the outcome of two different recovery paths after standard of care bariatric surgery. The difference between both recovery paths is that half of the patients will get the standard of care by staying one night in the hospital before returning home (group B), while the other half will receive a Healthdot directly after surgery and leave the hospital on the same day (evening) (group A). 200 patients will be recruited and can choose whether they want to be assigned to the the regular recovery path or receive a Healthdot and leave the hospital on the same day. If they have no preference they will be randomly assigned to one of the two groups. Patients in the outpatient recovery group will wear the Healthdot for 7 days at home and vital signs (heart rate and respiratory rate, together with context data on activity and posture) will be transmitted to the hospital to monitor recovery. The study is mainly designed to investigate if the clinical outcome in both groups is equal (non-inferiority) based on a combined outcome measures like 30 days readmission rate and patient satisfaction.

Condition or Disease Intervention/Treatment Phase
  • Device: Healthdot application
 N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
208 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Postbariatric EArly Discharge Controlled by Healthdot (PEACH)
Actual Study Start Date :
Feb 22, 2021
Actual Primary Completion Date :
Dec 25, 2021
Actual Study Completion Date :
Dec 25, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Group A

Healthdot directly after surgery and leave the hospital on the same day (evening) (group A)

Device: Healthdot application
Healthdot device is applied on subject's chest after surgery
No Intervention: Group b

Standard of care by staying one night in the hospital before returning home (group B)

Outcome Measures

Primary Outcome Measures

  1. Mortality [Within 30 days after primary surgery]

    Mortality will be determined from the patient medical record

  2. Severe postoperative complications (Clavien-Dindo IIIb or higher) [Within 30 days after primary surgery]

    Severe postoperative complications will be determined from the patient medical record

  3. Readmission (at least one night in hospital) [Within 30 days after primary surgery]

    Readmission will be determined from the patient medical record

  4. Mild complications (Clavien-Dindo II and IIIa) [Within 30 days after primary surgery]

    Mild complications will be determined from the patient medical record

  5. Prolonged length of stay (3 days or more in hospital) [Within 30 days after primary surgery]

    Prolonged length of stay will be determined from the patient medical record

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  • Adult (equal or above 18)

  • Approval for primary bariatric surgery (gastric sleeve or bypass) by a multidisciplinary bariatric team

  • Willing and able to sign informed consent form

  • Able to understand instructions

  • In possession of a telephone on which patient can be reached for the duration of participation (day 1-8)

  • An adult person must be present at the same location as the patient during the first night following surgery who is able to mobilize help or seek medical care if necessary.

Exclusion Criteria:

  • Patients of psychiatric wards, inmates of prisons, or other state institutions

  • Investigator or any other team member involved directly or indirectly in the conduct of the clinical study

  • Any skin condition, for example prior rash, discoloration, scars or open wounds at the area (Left lower rib) where the Healthdot needs to be placed

  • Known allergy for the tissue adhesive used in the Healthdot (white band-aid)

  • Use of topical that is known to influence the skin at the test area (such as medical and non-medical creams or lotions)

  • Patient with active implantables such as Implantable Cardioverter Defibrilator (ICD) and pacemaker

  • Expected participation less than 8 days

  • Left lower rib (place where Healthdot will be applied) is involved in the area of surgery, area of disinfection or area where bandages are needed.

  • Patients with antibiotic resitant infections (e.g. MRSA)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Catharina Hospital Eindhoven Noord-Brabant Netherlands 5623 EJ

Sponsors and Collaborators

  • Philips Electronics Nederland B.V. acting through Philips CTO organization

Investigators

  • Principal Investigator: Simon Nienhuijs, Catharina Hospital, Eindhoven, The Netherlands

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Philips Electronics Nederland B.V. acting through Philips CTO organization
ClinicalTrials.gov Identifier:
NCT04754893
Other Study ID Numbers:
  • ICBE-2-36455
First Posted:
Feb 15, 2021
Last Update Posted:
Jun 30, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Jun 30, 2022